# Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

> **NCT01738347** · PHASE1 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 30 (estimated)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis (rrMS)

## Interventions

- **DRUG:** Arm 1 - GEH120714 (18F) Injection

## Key facts

- **NCT ID:** NCT01738347
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01738347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01738347, "Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01738347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*